From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB

Brian S. Barnett; Franklin King

doi:10.1001/jamapsychiatry.2026.1901

July 15, 2026JAMA Psychiatry

From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB

View at Publisher

Ask AI

Bookmark

Share

Key Points

This viewpoint aims to analyze the regulatory journey of sodium oxybate as a model for psychedelic substances.
Reviewed the regulatory history of sodium oxybate (GHB).
Discussed implications for the development of psychedelics and Schedule I substances.
Sodium oxybate was successfully transitioned from Schedule I to clinical use.
The regulatory pathway highlights potential pathways for psychedelic drug development.

Implication

Viewpoint examines the regulatory pathway of sodium oxybate to inform psychedelic drug development.

Abstract

This Viewpoint reviews the case of sodium oxybate, a product of gamma-hydroxybutyrate (GHB), to illustrate how psychedelics and other Schedule I substances can proceed through a similar regulatory pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Barnett et al. (2026) studied this question.

synapsesocial.com/papers/6a59c60da58755010b4714dd https://doi.org/10.1001/jamapsychiatry.2026.1901

View at Publisher

Ask AI

Bookmark

Share

From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB

Key Points

Implication

Abstract

Discussion

Cite This Study

From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading